EcoDrugPlus

Proteasomal Ubiquitin Receptor Adrm1-Like

Ensembl ID : ENSNFUG00015011063
Gene Symbol: LOC107389462
3 Cross references
191 Possible Orthologues:

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSNFUG00015017024
Gene Symbol: PSMA1
1 Cross references
270 Possible Orthologues:

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSNFUG00015004157
Gene Symbol: PSMA2
3 Cross references
269 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSNFUG00015004831
Gene Symbol: PSMA3
1 Cross references
238 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSNFUG00015010422
Gene Symbol: PSMA4
3 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSNFUG00015015714
Gene Symbol: PSMA5
3 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSNFUG00015015657
Gene Symbol: PSMA6
3 Cross references
244 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSNFUG00015006600
Gene Symbol: PSMA8
1 Cross references
182 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSNFUG00015007077
Gene Symbol: PSMB1
3 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 11b

Ensembl ID : ENSNFUG00015018537
Gene Symbol: PSMB11B
1 Cross references
159 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSNFUG00015015575
Gene Symbol: PSMB2
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSNFUG00015017164
Gene Symbol: PSMB3
3 Cross references
260 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).